value - Stock trades at 0.9x P/S and 5.8x EV/EBITDA with 15% FCF yield, attracting deep value investors betting on stabilization.
Rising rates negatively impact valuation multiples for unprofitable growth companies, though GoodRx achieved GAAP profitability in 2025.
Watch on earnings: US uninsured rate and underinsured population trends - addressable market size for cash-pay solutions, Generic drug dispensing rate (currently ~90% of prescriptions) - GoodRx captures more value on generics, PBM industry consolidation and vertical integration announcements - structural threat indicators.
One Sentence Summary:
GoodRx: the story is balanced — monthly active consumer (mac) growth and retention rates - declining macs signal competitive displacement.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.